NEUROLOGIE PRO PRAXI / Neurol. praxi. 2024;25(6):441-444 / www.neurologiepropraxi.cz 444 HLAVNÍ TÉMA Tenektepláza v liečbe ischemickej NCMP a prematurely terminated randomized clinical trial. Stroke. 2010;41:707-711. 12. Huang X, Cheripelli BK, Lloyd SM, et al. Alteplase versus tenecteplase for thrombolysis after ischemic stroke (ATTEST): a phase 2, randomized, open-label, blinded endpoint study. Lancet Neurology. 2015;14:368-376. 13. Huang X, MacIsaac R, Thompson JL, et al. Tenecteplase versus alteplase in stroke thrombolysis: an individual patient data meta-analysis of randomized controlled trials. International Journal of Stroke. 2016;11:534-543. 14. Katsanos AH, Safouris A, Sarraj A, et al. Intravenous thrombolysis with tenecteplase in patients with large vessel occlusions: systematic review and meta-analysis. Stroke. 2021;52:308-312. 15. Kvistad CE, Næss H, Helleberg BH, et al. Tenecteplase versus alteplase for the management of acute ischemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomized, open- -label, blinded endpoint, non-inferiority trial. Lancet Neurology. 2022;21:511-519. 16. Li S, Pan Y, Wang Z, et al. Safety and efficacy of tenecteplase versus alteplase in patients with acute ischemic stroke (TRACE): a multicenter, randomized, open label, blinded- -endpoint (PROBE) controlled phase II study. Stroke Vascular Neurology. 2022;7:47-53. 17. Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischemic stroke (NOR- -TEST): a phase 3, randomized, open-label, blinded endpoint trial. Lancet Neurology. 2017;16:781-788. 18. Ma Y, Xiang H, Busse JW, et al. Tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis of randomized and non-randomized studies. J Neurol. 2024;271:2309-2323. 19. Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischemic stroke in Canada (AcT): a pragmatic, multicenter, open-label, registry-linked, randomized, controlled, non-inferiority trial. Lancet. 2022;400:161-169. 20. Muir GFK, Ford I, Wardlaw JM, et al. Tenecteplase versus alteplase for acute stroke within 4.5 hours of onset: the second alteplase-tenecteplase trial evaluation for stroke thrombolysis (ATTEST-2). (2023). 21. Ouriel K. Safety and efficacy of various thrombolytic agents. Reviews in Cardiovascular Medicine. 2002;3(Suppl 2):S17. 22. Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine. 2012;366:1099-1107. 23. Roaldsen MB, Eltoft A, Wilsgaard T, et al. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicenter, open-label, randomized controlled trial. Lancet Neurology. 2023;22:117-126. 24. Ross AM. New plasminogen activators a clinical review. Clinical Cardiology. 1999;22:165-171. 25. Serebruany VL, Malinin AI, Callahan KP, et al. Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: The Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. American Heart Journal. 2003;145(4):636-642. 26. Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clinical Pharmacokinetics. 2002;41(15):1229-1245. 27. Wang Y, Li S, Pan Y, et al., TRACE-2 Investigators. Tenecteplase versus alteplase in acute ischemic cerebrovascular events (TRACE-2): a phase 3, multicenter, open-label, randomized controlled, non-inferiority trial. Lancet. 2023;401:645-654. 28. Xiong Y, Wang L, Li G, et al. Tenecteplase versus alteplase for acute ischemic stroke: a meta-analysis of phase III randomized trials. Stroke Vascular Neurology. 2023;28:svn2023-002396. PŘEDPLATNÝM ČASOPISU NA ROK 2025 ZÍSKÁTE: 20% slevu na kongresy* pořádané společností SOLEN 5× Neurologie pro praxi ve vaší schránce Tematická suplementa Přístup do archivu časopisu on-line * platí pro kongresy uvedené v seznamu Objednávejte www.neurologiepropraxi.cz predplatne@solen.cz Už máte předplaceno? Cena předplatného na rok 2025 1 980 Kč (5 čísel/rok)
RkJQdWJsaXNoZXIy NDA4Mjc=